US/UK/Canada

Share

Contacts

  • Orexo
    Box 303 751 05 Uppsala
    +46 (0)18 780 88 00
    +46 (0)18 780 88 88
    http://www.orexo.com

    • Quotes

    With the acquisition of the rights to two digital health products from GAIA and the appointment of Dennis, a thought leader in the digital health industry in the US, we are well positioned to lead this development within the complementary disease areas of our pharmaceutical business.
    Nikolaj Sørensen, President and CEO
    Our strategy is to focus on solutions with scientifically proven therapeutic effect which will benefit the healthcare system as a whole and more importantly patients.
    Nikolaj Sørensen, CEO, about Digital Therapies
    I am convinced that DTx will become an integral and natural part of addiction treatment in the future. This digital therapy for OUD patients is perfectly positioned with Orexo’s competences and commercial organization in the US.
    Nikolaj Sørensen, President and CEO
    Mundipharma Australia has been a good partner in the approval process and we are confident that their experience and infrastructure will create a strong foundation for a successful launch of Zubsolv®
    Nikolaj Sørensen, President and CEO
    Pick a time period -
    Tags ( Active)

    Orexo's lead product ZUBSOLV® added to NY State Medicaid MAT Preferred Drug List

    · ZUBSOLV® will be available to all patients with Medicaid insurance in NY state effective March 22, 2022 · ZUBSOLV® market access improves in the public segment to 48 percent unrestricted access from 42 percent currently · ZUBSOLV® maintains unrestricted access to over 98 percent of patients in commercial segment Uppsala, Sweden – February 24, 2022 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), announced today information about improved market access position for ZUBSOLV® (buprenorphine and naloxone) sublingual tablet (CIII) for opioid dependence. This news follows the publication

    Orexo announces first patient enrolled in pivotal study evaluating the efficacy of modia™ in combination with sublingual buprenorphine/ naloxone for the treatment of OUD

    · The digital therapeutic can be a valuable addition to clinician supervised medication-assisted treatment programs for individuals with opioid use disorder (OUD) · The study is designed to enroll an estimated 400 participants at 35 sites across the US · Orexo brings deep category expertise to the research effort, having served the US OUD market extensively over the last eight years Uppsala, Sweden – July 1, 2021 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces the enrollment of the first participant in the pivotal study of digital therapeutic modia™, in combination

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media